BMO raises Bristol-Myers Squibb stock price target on Eliquis beat

BMO Capital raised its price target on Bristol-Myers Squibb to $60 from an undisclosed prior level while keeping a Market Perform rating, citing improving near-term expectations. The firm lifted its 2026 revenue estimate to $16.4 billion from $16.1 billion, but noted ongoing pressure from generic competition for Revlimid and Pomalyst, Eliquis loss of exclusivity, and IRA-related declines. Bristol-Myers also reported Q1 2026 EPS of $1.58 versus $1.42 expected and revenue of $11.49 billion versus $10.92 billion, while maintaining a 4.16% dividend yield.

Analysis

The market is rewarding Bristol not just for cleaner near-term numbers, but for evidence that the post-patent cliff may be more elongated than feared. The key second-order effect is that slower erosion on legacy cash flows buys time for management to sequence catalysts, which matters because the valuation debate is now less about this quarter’s print and more about whether the 2026-27 readout stack can re-rate the terminal multiple.

The bigger winner from this setup may be the income base itself: a defended dividend plus incremental visibility tends to compress downside volatility, which can keep the stock bid even if pipeline data are only “good enough.” That creates a subtle asymmetry versus other large-cap pharma names with similar patent cliffs but weaker balance sheets or less credible late-stage depth; capital can migrate toward the cleanest bridge story rather than the highest headline growth.

The risk is that investors are implicitly paying for multiple shots on goal, while the actual binary conversion rate remains low. If the first major readout disappoints, the market will likely de-rate the entire 2030s bridge thesis within days, not months, because the stock is already near highs and expectations have clearly moved up.

On Cytokinetics, any indirect benefit is likely to be tactical rather than fundamental. If Bristol’s broader cardiac update improves sentiment around the mechanism class, that can support a short-lived sympathy bid, but the real driver will still be patient selection and trial design; this is not a clean read-through worth underwriting as durable alpha.

Key Decisions for Investors

• Maintain a tactical long in BMY into the 2H26 catalyst window, but hedge with short-dated downside protection; the setup favors a low-volatility carry trade until the first major readout, with asymmetric downside if data miss.
• For new money, consider a pairs trade: long BMY / short a weaker large-cap pharma with a similar patent-cliff overhang but less credible pipeline visibility; the relative-value thesis is that capital will continue to concentrate in the best-funded bridge story.
• Sell upside against existing BMY longs via covered calls 5-10% above spot over the next 1-3 months; near-term upside looks capped after the rerating, while dividend support limits immediate downside.
• Avoid chasing CYTK on this headline alone; if used at all, treat it as a short-term event-driven trade with tight risk limits rather than a thesis position.
• Set a hard review point ahead of the first meaningful clinical catalyst: if guidance or consensus begins to discount failure probabilities above 50%, reduce exposure before the market reprices the full pipeline stack.